181 related articles for article (PubMed ID: 33351064)
1. Postoperative outcomes of lung transplant recipients with preformed donor-specific antibodies.
Kayawake H; Chen-Yoshikawa TF; Gochi F; Tanaka S; Yurugi K; Hishida R; Yutaka Y; Yamada Y; Ohsumi A; Hamaji M; Nakajima D; Date H
Interact Cardiovasc Thorac Surg; 2021 Apr; 32(4):616-624. PubMed ID: 33351064
[TBL] [Abstract][Full Text] [Related]
2. A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome.
Parquin F; Zuber B; Vallée A; Taupin JL; Cuquemelle E; Malard S; Neuville M; Devaquet J; Le Guen M; Fessler J; Beaumont L; Picard C; Hamid A; Colin de Verdière S; Grenet D; De Miranda S; Glorion M; Sage E; Pricopi C; De Wolf J; Brun AL; Longchampt E; Cerf C; Roux A; Brugière O
Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 34016620
[TBL] [Abstract][Full Text] [Related]
3. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
4. Comparison of de novo donor-specific antibodies between living and cadaveric lung transplantation.
Gochi F; Chen-Yoshikawa TF; Kayawake H; Ohsumi A; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Hamaji M; Yurugi K; Hishida R; Date H
J Heart Lung Transplant; 2021 Jul; 40(7):607-613. PubMed ID: 34078558
[TBL] [Abstract][Full Text] [Related]
5. The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.
Shino MY; Zhang Q; Li N; Derhovanessian A; Ramsey A; Saggar R; Britton IN; Amubieya OO; Lari SM; Hickey M; Reed EF; Noble PW; Stripp BR; Fishbein GA; Lynch JP; Ardehali A; Sayah DM; Weigt SS; Belperio JA
Am J Transplant; 2022 Feb; 22(2):565-573. PubMed ID: 34464505
[TBL] [Abstract][Full Text] [Related]
6. Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.
Verleden SE; Vanaudenaerde BM; Emonds MP; Van Raemdonck DE; Neyrinck AP; Verleden GM; Vos R
Eur Respir J; 2017 Nov; 50(5):. PubMed ID: 29146602
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JSF; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
Am J Transplant; 2018 Sep; 18(9):2274-2284. PubMed ID: 29464832
[TBL] [Abstract][Full Text] [Related]
8. Donor-Specific HLA Antibodies in Living Versus Deceased Donor Liver Transplant Recipients.
Levitsky J; Kaneku H; Jie C; Walsh RC; Abecassis M; Tambur AR
Am J Transplant; 2016 Aug; 16(8):2437-44. PubMed ID: 26896194
[TBL] [Abstract][Full Text] [Related]
9. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation.
Kim H; Yi NJ; Song EY; Lee K; Lee KW; Lee HW; Ahn HY; Yoon KC; Hong SK; Suh KS
Clin Transplant; 2018 May; 32(5):e13244. PubMed ID: 29577436
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib versus rituximab for treatment of de novo donor-specific antibodies in lung transplant recipients.
Razia D; Hu C; Cherrier L; Nasar A; Walia R; Tokman S
Transpl Immunol; 2022 Dec; 75():101703. PubMed ID: 36049718
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of a Steroid Avoidance Immunosuppression Regimen in Renal Transplant Patients With De Novo or Preformed Donor-Specific Antibodies: A Single-Center Study.
Schutt R; Case J; Kurian SM; Spierling Bagsic SR; Barrick BL; Toll AE; Zhang Q; Reed EF; Quigley MM; Schaffer R; Fisher JS; Rice JC; Marsh CL
Transplant Proc; 2021 Apr; 53(3):950-961. PubMed ID: 33293041
[TBL] [Abstract][Full Text] [Related]
12. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation.
O'Leary JG; Kaneku H; Jennings LW; Bañuelos N; Susskind BM; Terasaki PI; Klintmalm GB
Liver Transpl; 2013 Sep; 19(9):973-80. PubMed ID: 23780820
[TBL] [Abstract][Full Text] [Related]
13. A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival.
Michielsen LA; Wisse BW; Kamburova EG; Verhaar MC; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JF; Hepkema BG; Lambeck AJ; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens M; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KA; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG; van Zuilen AD
Nephrol Dial Transplant; 2019 Jun; 34(6):1056-1063. PubMed ID: 30365008
[TBL] [Abstract][Full Text] [Related]
14. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.
Gosset C; Viglietti D; Rabant M; Vérine J; Aubert O; Glotz D; Legendre C; Taupin JL; Duong Van-Huyen JP; Loupy A; Lefaucheur C
Kidney Int; 2017 Sep; 92(3):729-742. PubMed ID: 28554738
[TBL] [Abstract][Full Text] [Related]
15. Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.
Brugière O; Roux A; Le Pavec J; Sroussi D; Parquin F; Pradère P; Dupin C; Bunel V; Mourin G; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Mal H; Suberbielle C; Gautreau C; Caillat-Zucman S; Cazes A; Thabut G; Taupin JL
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976654
[TBL] [Abstract][Full Text] [Related]
16. Preformed C1q-binding Donor-specific Anti-HLA Antibodies and Graft Function After Kidney Transplantation.
Okabe Y; Noguchi H; Miyamoto K; Kaku K; Tsuchimoto A; Masutani K; Nakamura M
Transplant Proc; 2018 Dec; 50(10):3460-3466. PubMed ID: 30577221
[TBL] [Abstract][Full Text] [Related]
17. The fraction of sensitization among lung transplant recipients in a transplant center in Japan.
Kumata S; Hirama T; Watanabe Y; Oishi H; Niikawa H; Akiba M; Tikkanen J; Okada Y
BMC Pulm Med; 2020 Oct; 20(1):256. PubMed ID: 33008353
[TBL] [Abstract][Full Text] [Related]
18. Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work?
Vacha M; Chery G; Hulbert A; Byrns J; Benedetti C; Finlen Copeland CA; Gray A; Onwuemene O; Palmer SM; Snyder LD
Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 27988971
[TBL] [Abstract][Full Text] [Related]
19. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
[No Abstract] [Full Text] [Related]
[Next] [New Search]
